MedTrace Logo

Evaluating Quality of Life Benefits of ACUVUE® Theravision® With Ketotifen in Subjects With Ocular Allergies

NCT05530889 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-02-01

No results posted yet for this study

Summary

This will be a prospective, randomized, bilateral eye, crossover, non-masked single site pilot study to compare the severity of symptoms of itching between test and control lens after two weeks of wear.

Conditions

  • Ocular Physiology

Interventions

DEVICE

TEST Lens

ACUVUE® Theravision® with Ketotifen

DEVICE

CONTROL Lens

1-DAY ACUVUE® MOIST.

Sponsors & Collaborators

  • Johnson & Johnson Vision Care, Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Vision Care, Inc. Clinical Trial · Johnson & Johnson Vision Care, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2024-05-13
Completion
2024-05-13
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05530889 on ClinicalTrials.gov